Percutaneous coronary intervention with the TandemHeart™ percutaneous left ventricular assist device support: Six years of experience and outcomes

Nascimbene, Angelo; Loyalka, Pranav; Gregorič, Igor D.; Kar, Biswajit

doi:10.1002/ccd.26147

Cited by 11 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another group, from Texas in the US, evaluated 74 PCIs supported by a TandemHeart from 2005 to 2011. 50 Among patients without cardiogenic shock who were not eligible for surgery because of coronary anatomy or comorbidities, survival rates were 88-94% at 30 days, and 64-75% at 1 year.…”

Section: Tandemheartmentioning

confidence: 99%

Use of Mechanical Circulatory Support in Complex High-risk Percutaneous Coronary Intervention: A Review of Current Evidence

Sung,

Lam,

Chui

et al. 2023

J Asian Pac Soc Cardiol

View full text Add to dashboard Cite

With advances in devices and techniques of percutaneous coronary intervention (PCI), interventional cardiologists are managing patients with coronary artery disease of increasing complexity. For patients with prohibitive operative risk or who refuse bypass surgery, PCI may provide a reasonable alternative. Procedural haemodynamic stress often poses a significant challenge and is poorly tolerated in patients with reduced myocardial reserve, such as those with advanced heart failure or extreme frailty. The emergence of new mechanical circulatory support (MCS) devices has made PCI a more viable option for these high-risk patients. In this article, the authors review the existing evidence on the use of MCS in non-emergency complex and high-risk PCI, the optimal timing of initiating MCS and barriers to MCS use.

show abstract

Section: Tandemheartmentioning

confidence: 99%

Use of Mechanical Circulatory Support in Complex High-risk Percutaneous Coronary Intervention: A Review of Current Evidence

Sung,

Lam,

Chui

et al. 2023

J Asian Pac Soc Cardiol

View full text Add to dashboard Cite

show abstract

“…En 2012, Alli et al 50 llevaron a cabo un estudio retrospectivo que analizó 54 pacientes que se sometieron a ICP bajo soporte con TandemHeart entre 2004 y 2009, con una tasa de éxito de la ICP del 97% (el 62% de los pacientes tenían enfermedad multivaso o del TCI). La supervivencia total a los 30 días fue del 90%, y se mantuvo a los 6 meses, pero destaca una tasa de complicaciones vasculares del 13% 50,51 .…”

Section: Situación Actual En La Icpunclassified

Asistencias ventriculares percutáneas en los pacientes agudos y en el intervencionismo coronario de alto riesgo

Gómez-Polo¹,

Villablanca²,

Ramakrishna³

2021

RECIC

View full text Add to dashboard Cite

La intervención coronaria percutánea (ICP) desempeña un papel fundamental en el tratamiento de los pacientes con enfermedad coronaria obstructiva. De ellos, un porcentaje significativo se someterán a un procedimiento de alto riesgo, en función de la presentación clínica, las características del paciente y su anatomía coronaria. Los dispositivos de asistencia ventricular izquierda, como el balón intraaórtico de contrapulsación, el dispositivo TandemHeart, el Impella, los dispositivos HeartMate PHP y las técnicas de oxigenación veno-arterial con oxigenador extracorpóreo de membrana (ECMO), son herramientas empleadas para proporcionar soporte circulatorio en la ICP de alto riesgo, con un impacto creciente en la práctica clínica. Existen numerosos trabajos en la literatura científica sobre su empleo en este escenario, con resultados controvertidos. Esta revisión proporciona una visión general de la evidencia disponible sobre el empleo de los distintos tipos de dispositivos, así como de su potencial papel en la ICP de alto riesgo.Palabras clave: Balón intraaórtico de contrapulsación. Dispositivo de asistencia ventricular izquierda. Intervencionismo coronario percutáneo de alto riesgo. Shock cardiogénico. Ventrículo derecho. Left ventricular assist devices in acute cardiovascular care patients and high-risk percutaneous coronary interventions ABSTRACTPercutaneous coronary intervention (PCI) plays a key role in the management of patients with obstructive coronary artery disease. Besides, depending on the patients' clinical presentation, characteristics, comorbidities, and coronary anatomy, an increasing number of patients will undergo a high-risk PCI. Left ventricular assist devices, as the intra-aortic balloon pump, TandemHeart, Impella, HeartMate PHP, and extracorporeal membrane oxygenation are useful tools to provide circulatory support for high-risk PCIs. Some studies and trials have assessed its impact on this clinical scenario with controversial results. This review provides an overview on the scientific evidence available on the use of left ventricular assist devices and their potential role in high-risk PCI.

show abstract

“…Whereas the methods of implantation, hemodynamic effects, and pump mechanics of these two devices differ, they work on a common principle of maintaining perfusion, decompressing the left ventricle, and minimizing oxygen requirement in the left ventricle . pVADs have consistently demonstrated far superior hemodynamic profiles compared to IABPs in all trials, which albeit did not translate into survival benefit . Furthermore, with increasing utilization of pVADs, hospitalizations associated with them and their complications have a significant impact on healthcare utilizations and cost.…”

Section: Introductionmentioning

confidence: 99%

Trends, etiologies, and predictors of 90‐day readmission after percutaneous ventricular assist device implantation: A national population‐based cohort study

Virk

Tripathi

Gupta

et al. 2018

Clinical Cardiology

View full text Add to dashboard Cite

Percutaneous ventricular assist devices (pVADs) are indicated to provide hemodynamic support in high-risk percutaneous interventions and cardiogenic shock. However, there is a paucity of published data regarding the etiologies and predictors of 90-day readmissions following pVAD use. We studied the data from the US Nationwide Readmissions Database (NRD) for the years 2013 and 2014. Patients with a primary discharge diagnosis of pVAD use were collected by searching the database for International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedural code 37.68 (Impella and TandemHeart devices). Amongst this group, we examined 90-day readmission rates. Comorbidities as identified by "CM_" variables provided by the NRD were also extracted. The Charlson Comorbidity Index was calculated using appropriate ICD-9-CM codes, as a secondary diagnosis. A 2-level hierarchical logistic regression model was then used to identify predictors of 90-day readmission following pVAD use. Records from 7074 patients requiring pVAD support during hospitalization showed that 1562 (22%) patients were readmitted within 90 days. Acute decompensated heart failure (22.6%) and acute coronary syndromes (11.2%) were the most common etiologies and heart failure (odds ratio [OR]: 1.39, 95% confidence interval [CI]: 1.17-1.67), chronic obstructive pulmonary disease (OR: 1.26, 95% CI: 1.07-1.49), peripheral vascular disease (OR: 1.305, 95% CI: 1.09-1.56), and discharge into short- or long-term facility (OR: 1.28, 95% CI: 1.08-1.51) were independently associated with an increased risk of 90-day readmission following pVAD use. This study identifies important etiologies and predictors of short-term readmission in this high-risk patient group that can be used for risk stratification, optimizing discharge, and healthcare transition decisions.

show abstract

Percutaneous coronary intervention with the TandemHeart™ percutaneous left ventricular assist device support: Six years of experience and outcomes

Abstract: TandemHeart™ assisted PCI is a viable option for revascularization in cases of profound cardiogenic shock or extremely risky intervention due to complex anatomy. © 2015 Wiley Periodicals, Inc.

Cited by 11 publications

References 20 publications

Use of Mechanical Circulatory Support in Complex High-risk Percutaneous Coronary Intervention: A Review of Current Evidence

Use of Mechanical Circulatory Support in Complex High-risk Percutaneous Coronary Intervention: A Review of Current Evidence

Asistencias ventriculares percutáneas en los pacientes agudos y en el intervencionismo coronario de alto riesgo

Trends, etiologies, and predictors of 90‐day readmission after percutaneous ventricular assist device implantation: A national population‐based cohort study

Contact Info

Product

Resources

About